Figure 5.
Analysis of gene alterations using Guardant360. (A) Frequency of gene alterations before treatment; (B) progression-free survival according to the change of positivity of EGFR mutations between before treatment and day 22; (C) overall survival according to the change of positivity of EGFR mutations between before treatment and day 22; (D) progression-free survival according to the TP53 mutations; (E) overall survival according to the TP53 mutations.